Lipocine Inc. LPCN
Set alert
At close · Oct 30
After hours · Oct 30, 4:53 PM ET
- YTD
- -82.07%
- 1 year
- -44.62%
- Open
- 1.50
- Prev close
- 1.52
- Mkt cap
- 11.87M
- Vol
- 112.05K
- Avg vol
- 1.80M
- EPS
- -1.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.42
- High
- 1.50
- Forward P/E
- -3.87
- Beta
- 1.19
- Short ratio
- 2.80
- Inst. own
- 9.96%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.16
- 200-d avg
- 5.39
- 1y target
- 21.50
News
3 weeks ago zacks.com
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
3 weeks ago benzinga.com
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
3 weeks ago benzinga.com
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Health Canada has given the go-ahead to Lipocine Inc. (NASDAQ:LPCN) and its licensing partner, Verity Pharmaceuticals Inc., for TLANDO (testosterone undecanoate) capsules.
3 weeks ago benzinga.com
Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada
Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharma plans a launch by the end of 2026.
3 weeks ago benzinga.com
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday's pre-market session. Lipocine (NASDAQ:LPCN) shares rose 52.38% to $3.2. The company's market cap…
3 weeks ago prnewswire.com
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through…
-
3 weeks ago benzinga.com
Lipocine Licensing Partner Verity Pharmaceuticals Receives Health Canada Approval For TLANDO Capsules For Testosterone Replacement Therapy In Adult Males
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine’s licensing partner Verity…
1 month ago zacks.com
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Neutral on Lipocine, Announces $4 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Neutral and announces $4 price target.
1 month ago prnewswire.com
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned;…
1 month ago prnewswire.com
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company…
2 months ago prnewswire.com
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results…
-
2 months ago benzinga.com
Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41)…
3 months ago prnewswire.com
Lipocine Appoints Michael J. Grissinger to Board of Directors
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral…
5 months ago prnewswire.com
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time SALT LAKE CITY, June 4, 2026 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company focused on…
-
5 months ago benzinga.com
Lipocine To Announce Phase 3 Data For LPCN 1154 Treatment For Postpartum Depression On May 26
Oral Presentation detailsTitle:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154Presenter:Benjamin Bruno,…
5 months ago prnewswire.com
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral…
5 months ago globenewswire.com
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and…
5 months ago prnewswire.com
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral…
-
5 months ago benzinga.com
CORRECTION: Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397K Miss $162.500K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 54.29 percent decrease over losses of $(0.35)…
5 months ago zacks.com
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
Lipocine (LPCN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.35 per share a year ago.
5 months ago prnewswire.com
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral…
6 months ago defenseworld.net
Mangoceuticals (NASDAQ:MGRX) versus Lipocine (NASDAQ:LPCN) Financial Contrast
Mangoceuticals (NASDAQ: MGRX - Get Free Report) and Lipocine (NASDAQ: LPCN - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies…
6 months ago defenseworld.net
John Higuchi Buys 40,000 Shares of Lipocine (NASDAQ:LPCN) Stock
Lipocine Inc. (NASDAQ: LPCN - Get Free Report) Director John Higuchi acquired 40,000 shares of the company's stock in a transaction that occurred on Tuesday, April 7th. The shares were bought at an…
6 months ago defenseworld.net
Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock
Lipocine Inc. (NASDAQ: LPCN - Get Free Report) CEO Mahesh Patel bought 25,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was bought at an average cost of $2.03 per…
6 months ago benzinga.com
What's Going On With Carvana Stock Monday?
BofA downgrades Carvana (CVNA) to Neutral, cutting the price target to $360. Explore the latest analyst insights and technical support levels.
6 months ago benzinga.com
What's Going On With Lipocine Stock On Monday?
On Thursday, the company said LPCN 1154 did not meet its primary endpoint in a Phase 3 trial for postpartum depression (PPD).
6 months ago benzinga.com
What's Going On With Lipocine Stock On Monday?
Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouraging subgroup data.
6 months ago benzinga.com
This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Wall Street analysts changed their outlook on top names. Check out the ratings page for complete changes. Check out what analysts think about CVNA.
6 months ago globenewswire.com
Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ: LPCN). The investigation focuses on Lipocine's…
7 months ago benzinga.com
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results
US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Quarry Inc. and Cocrystal Pharma Inc. shares increase.
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
7 months ago benzinga.com
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint
Lipocine said LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 in the overall study population, and the primary…
7 months ago benzinga.com
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint
Lipocine Inc. shares are trading lower Thursday after reporting topline safety and efficacy results for LPCN 1154 in postpartum depression.
7 months ago benzinga.com
Nasdaq Down 1%; US Initial Jobless Claims Fall
US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer discretionary stocks fell. US jobless claims declined.
-
7 months ago benzinga.com
Lipocine's LPCN 1154 Misses Phase 3 Primary Endpoint in Postpartum Depression; Shows Early Efficacy Signals In Patients With Prior Psychiatric History And Maintains Favorable Safety Profile
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary…
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
9 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Lipocine, Raises Price Target to $15
HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and raises the price target from $7 to $15.
-
9 months ago benzinga.com
Lipocine Completes Enrollment, Patient Dosing In Its Phase 3 Clinical Study Of LPCN 1154 To Treat Postpartum Depression
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that enrollment…
-
9 months ago benzinga.com
Lipocine Completes Scheduled Independent Data Safety Monitoring Board Review Of Ongoing Phase 3 Clinical Trial evaluating LPCN 1154 For Rapid Relief Treatment Of PPD.
Company on track to report topline results early in the second quarter of 2026Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82…
-
10 months ago benzinga.com
Lipocine Granted U.S. Patent For Hydroxyprogesterone Caproate Compositions And Methods Of Use In Preventing Preterm Birth
https://ppubs.uspto.gov/api/pdf/downloadPdf/12502396?requestToken=eyJzdWIiOiJiNGI3ZTk4MS0wOTJiLTQyZjEtYmMzZi0wMDAyMTcyYjUyOTQiLCJ2ZXIiOiI5MzczYzJhZS0wZDkxLTQ4N2EtOGE3MC0xMmFkZTNhMmVhNTIiLCJleHAiOjB9
-
10 months ago benzinga.com
Lipocine Nears Full Enrollment In Phase 3 PPD Trial, Topline Results Expected Q2 2026
Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline results on track for the second quarter of 2026SALT LAKE CITY, Dec. 16, 2025 /PRNewswire/ -- Lipocine…
-
11 months ago benzinga.com
Lipocine Completes Scheduled Independent Data Safety Monitoring Board Review Of Phase 3 Trial Of LPCN 1154 In Postpartum Depression
Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as plannedMore than half of planned participants have completed dosing with no dose…
-
11 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Lipocine, Lowers Price Target to $7
HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and lowers the price target from $8 to $7.
-
12 months ago benzinga.com
Lipocine Q3 EPS $(0.59) Misses $(0.55) Estimate, Sales $114.574K Miss $238.000K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.55) by 8.26 percent. This is a 34.09 percent decrease over losses of $(0.44)…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.
-
1 year ago benzinga.com
CORRECTION: Lipocine Q2 EPS $(0.41) Misses $(0.40) Estimate, Sales $622.849K Beat $229.000K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.40) by 2.5 percent. This is a 26.79 percent increase over losses of $(0.56)…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintains $8 price target.